Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer

References

• Rosai J. Special techniques in surgical pathology. In: John RG, Jesse KM, Laura WL, Jeffrey LM, editors. Rosai and Ackerman’s Surgical Pathology. 9 edn ed. Edinburgh: Mosby; 2004:1810–1812.
   Google Scholar
• Lebeau A, Denkert C. Updated WHO classification of tumors of the breast: the most important changes. Pathologe. 2021;42(3):270–280. doi:10.1007/s00292-021-00934-9
   PubMed Web of Science ®Google Scholar
• Halpert B, Young MO. Carcinosarcoma of the mammary gland. Surgery. 1948;23:289–292.
   PubMed Web of Science ®Google Scholar
• Reis-Filho JSLS, Gobbi H, Sneige N. Metaplastic carcinoma. In: Lakhani S, Ellis I, Schnitt S, editors. World Health Organization Classification of Tumours of the Breast. 4 edn ed. Lyon: IARC; 2012:48–52.
   Google Scholar
• Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64:1490–1499. doi:10.1002/1097-0142(19891001)64:7<1490::AID-CNCR2820640722>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Tse GM, Tan PH, Putti TC, et al. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59:1079–1083. doi:10.1136/jcp.2005.030536
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605–613. doi:10.1093/annonc/mdl006
   PubMed Web of Science ®Google Scholar
• Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate. Ann Surg Oncol. 2011;18:94–103. doi:10.1245/s10434-010-1198-6
   PubMed Web of Science ®Google Scholar
• Yang YF, Liu J, Fang ZY, et al. Clinical features and prognosis of 25 cases of breast carcinosarcoma. Zhonghua Zhong Liu Za Zhi. 2012;34(34):620–623. doi:10.3760/cma.j.issn.0253-3766.2012.08.014
   PubMedGoogle Scholar
• Yakan S, Sarı E, Erkan N, et al. Breast carcinosarcomas. J Breast Health. 2014;10(3):161–165. doi:10.5152/tjbh.2014.2197
   PubMedGoogle Scholar
• Kennedy WR, Gabani P, Acharya S, et al. Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast. Cancer Med. 2019;8(4):1379–1388. doi:10.1002/cam4.1942
   PubMed Web of Science ®Google Scholar
• Ilhan E, Vardar E, Ozkok G, et al. A rare tumour of the breast: carcinosarcoma. J Clin Med Res. 2010;2:96–98. doi:10.4021/jocmr2010.03.275w
   PubMedGoogle Scholar
• Tian W, Xu D. Diagnosis and management of multiple carcinosarcoma of the breast in a young Chinese patient. Breast Care. 2012;7(2):147–149. doi:10.1159/000337772
   PubMed Web of Science ®Google Scholar
• Kang Y, Kang S, Li Q, et al. Mixed epithelial and mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast: a case report. Eur J Med Res. 2014;19(1):14. doi:10.1186/2047-783X-19-14
   PubMedGoogle Scholar
• Mele M, Jensen LL, Vahl P, et al. Breast carcinosarcoma: clinical and pathological features. Breast Dis. 2015;35(3):211–215. doi:10.3233/BD-150402
   PubMedGoogle Scholar
• Ghilli M, Mariniello DM, Fanelli G, et al. Carcinosarcoma of the breast: an aggressive subtype of metaplastic cancer. Report of a rare case in a Young BRCA-1 mutated woman. Clin Breast Canc. 2017;2017:17.
   Google Scholar
• Muslim S, Prasad G, Alam I, et al. Carcinosarcoma of breast mimicking breast abscess. Indian J Surg Oncol. 2018;9:398–401. doi:10.1007/s13193-018-0777-z
   PubMed Web of Science ®Google Scholar
• Thomas HR, Hu B, Boyraz B, et al. Metaplastic breast cancer: a review. Crit Rev Oncol Hematol. 2023;182:103924. doi:10.1016/j.critrevonc.2023.103924
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 4.2017, clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(3):310–320. doi:10.6004/jnccn.2018.0012
   PubMed Web of Science ®Google Scholar
• Schroeder MC, Rastogi P, Geyer CE, et al. Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010–2014. Oncologist. 2018;23(4):481–488. doi:10.1634/theoncologist.2017-0398
   PubMed Web of Science ®Google Scholar
• González-Martínez S, Pérez-Mies B, Carretero-Barrio I, et al. Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma. Cancers. 2020;12(7):1832. doi:10.3390/cancers12071832
   PubMed Web of Science ®Google Scholar
• Thomas A, Douglas E, Reis-Filho JS, et al. Metaplastic breast cancer: current understanding and future directions. Clin Breast Cancer;2023;2023:8209. doi:10.1016/j.clbc.2023.04.004
   Google Scholar
• Basho RK, Yam C, Gilcrease M, et al. Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and non metaplastic triple-negative breast cancer. Oncologist. 2018;23(11):1300–1309. doi:10.1634/theoncologist.2017-0498
   PubMed Web of Science ®Google Scholar
• Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274–4282. doi:10.1200/JCO.20.02151
   PubMed Web of Science ®Google Scholar
• Tray N, Taff J, Singh B, et al. Metaplastic breast cancers: genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast. 2019;44:29–32. doi:10.1016/j.breast.2018.12.010
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 2019;5(5):696–702. doi:10.1001/jamaoncol.2018.7098
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical Hodgkin lymphoma treated with sintilimab. EBioMedicine. 2020;54:102731. doi:10.1016/j.ebiom.2020.102731
   PubMed Web of Science ®Google Scholar